Top

Pediatric Nephrology

Published in:

01-08-2013 | Original Article

Long-term side effects of treatment with mTOR inhibitors in children after renal transplantation

Authors: Birgitta Kranz, Anne-Margret Wingen, Udo Vester, Jens König, Peter F. Hoyer

Published in: Pediatric Nephrology | Issue 8/2013

Abstract

Background

mTOR inhibitors (mTORI) have emerged as alternative and additive immunosuppressive agents in pediatric renal transplantation (pRTx). Their immunosuppressive, anti-proliferative, and anti-neoplastic mechanisms have been described to be effective, whereas some side effects are alarming. In particular, growth and pubertal development are of concern. The aim of this study was to look for long-term side effects of mTORI therapy in pRTx.

Patients and methods

The retrospective analysis focused on side effects, growth, and pubertal development under mTORI therapy in 31 children. Eighteen children were routinely monitored for estradiol, testosterone, LH, and FSH levels.

Results

The occurrence of bacterial infections, lymphoceles, myelosuppression, and the course of overall linear growth was comparable with other pediatric renal transplant cohorts. According to the clinical puberty status, all but one patient showed normal age-related development in parallel to normal serum hormone levels. Only one patient experienced cytomegaly virus infection under mTORI, no post-transplant lymphoproliferative disorders (PTLD) occurred.

Conclusions

Long-term mTORI therapy is safe in pRTx. No negative impact on growth and pubertal development was observed.

North American Pediatric Renal Trial and Collaborative Studies (NAPRTCS) (2010) annual transplant report https://web.emmes.com/study/ped/annlrept/2010_Report.pdf

Gaumann A, Schlitt HJ, Geissler EK (2008) Immunosuppression and tumor development in organ transplant recipients: the emerging dualistic role of rapamycin. Transpl Int 21:207–217CrossRefPubMed

Ettenger R, Hoyer PF, Grimm P, Webb N, Loirat C, Mahan JD, Mentser M, Niaudet P, Offner G, Vandamme-Lombaerts R, Hexham JM, Everolimus Pediatric Study Group (2008) Multicenter trial of everolimus in pediatric renal transplant recipients: results at three years. Pediatr Transplant 12:456–463CrossRefPubMed

Pape L, Lehner F, Blume C, Ahlenstiel T (2011) Pediatric kidney transplantation followed by de novo therapy with everolimus, low-dose cyclosporine A, and steroid elimination: 3-year data. Transplantation 92:658–662CrossRefPubMed

Powell HR, Kara T, Jones CL (2007) Early experience with conversion to sirolimus in a pediatric renal transplant population. Pediatr Nephrol 22:1773–1777CrossRefPubMed

Kasap B (2011) Sirolimus in pediatric renal transplantation. Pediatr Transpl 15:673–685CrossRef

Schwartz GJ, Haycock GB, Edelmann CM, Spitzer A (1976) A simple estimate of glomerular filtration rate in children derived from body length and plasma creatinine. Pediatrics 58:259–263PubMed

Schwartz GJ, Gauthier B (1985) A simple estimate of glomerular filtration rate in boys. J Pediatr 106:522–526CrossRefPubMed

Vester U, Kranz B, Nadalin S, Paul A, Becker J, Hoyer PF (2005) Sirolimus rescue of renal failure in children after combined liver-kidney transplantation. Pediatr Nephrol 20:686–689CrossRefPubMed

10.

Hymes LC, Warshaw BL (2011) Five-year experience using sirolimus-based calcineurine inhibitor-free immunosuppression in pediatric renal transplantation. Pediatr Transplant 15:437–441CrossRefPubMed

11.

Alvarez-Garcia O, Carbajo-Pérez E, Garcia E, Gil H, Molinos I, Rodriguez J, Ordoñez FA, Santos F (2007) Rapamycin retards growth and causes marked alterations in the growth plate of young rats. Pediatr Nephrol 22:954–961CrossRefPubMed

12.

Aoki MS, Miyabara EH, Soares AG, Saito ET, Moriscot AS (2006) mTOR pathway inhibition attenuates skeletal muscle growth induced by stretching. Cell Tissue Res 324:149–156CrossRefPubMed

13.

Guba M, Pratschke J, Hugo C, Krämer BK, Nohr-Westphal C, Brockmann J, Andrassy J, Reinke P, Pressmar K, Hakenberg O, Fischereder M, Pascher A, Illner WD, Banas B, Jauch KW, SMART-Study Group (2010) Renal function, efficacy and safety of sirolimus and mycophenolate mofetil after short-term calcineurin inhibitor-based quadruple therapy in de novo renal transplant recipients: one-year analysis of a randomized multicenter trial. Transplantation 90:175–183CrossRefPubMed

14.

Hymes LC, Warshaw BL (2011) Linear growth in pediatric renal transplant recipients receiving sirolimus. Pediatr Transplant 15:570–572PubMed

15.

Gonzalez D, Garcia CD, Azocar M, Waller S, Alonso A, Ariceta G, Mejia N, Santos F (2011) Growth of kidney-transplanted pediatric patients treated with sirolimus. Pediatr Nephrol 26:961–966CrossRefPubMed

16.

Höcker B, Weber LT, Feneberg R, Drube J, John U, Fehrenbach H, Pohl M, Zimmering M, Fründ S, Klaus G, Wühl E, Tönshoff B (2010) Improved growth and cardiovascular risk after late steroid withdrawal: 2-year results of a prospective, randomized trial in pediatric renal transplantation. Nephrol Dial Transpl 25:617–624CrossRef

17.

Boobes Y, Bernieh B, Saadi H, Al Hakim MR, Abouchacra S (2010) Gonadal dysfunction and infertility in kidney transplant patients receiving sirolimus. Int Urol Nephrol 42:493–498CrossRefPubMed

18.

Fritsche L, Budde K, Dragun D, Einecke G, Diekmann F, Neumayer HH (2004) Testosterone concentrations and sirolimus in male renal transplant patients. Am J Transplant 4:130–131CrossRefPubMed

19.

Offner G, Toenshoff B, Höcker B, Krauss M, Bulla M, Cochat P, Fehrenbach H, Fischer W, Foulard M, Hoppe B, Hoyer PF, Jungraithmayr TC, Klaus G, Latta K, Leichter H, Mihatsch MJ, Misselwitz J, Montoya C, Müller-Wiefel DE, Neuhaus TJ, Pape L, Querfeld U, Plank C, Schwarke D, Wygoda S, Zimmerhackl LB (2008) Efficacy and safety of basiliximab in pediatric renal transplant patients receiving cyclosporine, mycophenolate mofetil and steroids. Transplantation 86:1241–1248CrossRefPubMed

20.

Guba M, von Breitenbuch P, Steinbauer M, Koehl G, Flegel S, Hornung M, Bruns CJ, Zuelke C, Farkas S, Anthuber M, Jauch KW, Geissler EK (2002) Rapamycin inhibits primary and metastatic tumor growth by antiangiogenesis: involvement of vascular endothelial growth factor. Nat Med 8:128–135CrossRefPubMed

21.

Nashan B, Citterio F (2012) Wound healing complications and the use of Mammalian target of rapamycin inhibitors in kidney transplantation: a critical review of the literature. Transplantation 94:547–561CrossRefPubMed

Title: Long-term side effects of treatment with mTOR inhibitors in children after renal transplantation
Authors: Birgitta Kranz
Anne-Margret Wingen
Udo Vester
Jens König
Peter F. Hoyer
Publication date: 01-08-2013
Publisher: Springer Berlin Heidelberg
Published in: Pediatric Nephrology / Issue 8/2013
Print ISSN: 0931-041X
Electronic ISSN: 1432-198X
DOI: https://doi.org/10.1007/s00467-013-2459-y

Keynote webinar | Spotlight on sleep in brain health

Springer Medicine

Long-term side effects of treatment with mTOR inhibitors in children after renal transplantation

Abstract

Background

Patients and methods

Results

Conclusions

Keynote webinar | Spotlight on sleep in brain health

Springer Medicine

Abstract

Background

Patients and methods

Results

Conclusions

Please log in to get access to this content

Other articles of this Issue 8/2013

How benign is hematuria? Using genetics to predict prognosis

Author Index for the Abstracts for the IPNA Congress, 30 August - 3 September 2013, Shanghai, China

Abstracts for the IPNA Congress, 30 August - 3 September 2013, Shanghai, China

Ergocalciferol decreases erythropoietin resistance in children with chronic kidney disease stage 5

Pitfalls in diagnosing and treating children with renal artery hypertension: author’s reply

Prednisone in the treatment of tubulointerstitial nephritis in children